Search research articles
Contact Us
Filters
Showing results (231-240 of 253) with videos related to
Page
of 26
Sort By:
Molecular Oncology
|
September 7, 2025
PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer
Moriah L Cunningham, Jasibel Vasquez-Gonzalez, Samantha M Barnada, et al.
British Journal of Cancer
|
December 2, 2021
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
Julia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2018
Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Megan Li, Flora Mulkey, Chen Jiang, et al.
British Journal of Cancer
|
October 7, 2021
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
Julia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
JCO Precision Oncology
|
March 7, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Stacy Loeb, Scott W Keith, Heather H Cheng, et al.
Prostate Cancer and Prostatic Diseases
|
November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Joseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
European Urology Oncology
|
November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial
Fern Anari, John O'Neill, Woonyoung Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
Howard I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Neal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Cancer Discovery
|
September 7, 2023
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer
Sandra Santasusagna, Shijia Zhu, Vijayakumar Jawalagatti, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 253) with videos related to
Sort By:
Page
of 26
Molecular Oncology
|
September 7, 2025
PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer
Moriah L Cunningham, Jasibel Vasquez-Gonzalez, Samantha M Barnada, et al.
British Journal of Cancer
|
December 2, 2021
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
Julia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2018
Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Megan Li, Flora Mulkey, Chen Jiang, et al.
British Journal of Cancer
|
October 7, 2021
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
Julia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
JCO Precision Oncology
|
March 7, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Stacy Loeb, Scott W Keith, Heather H Cheng, et al.
Prostate Cancer and Prostatic Diseases
|
November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Joseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
European Urology Oncology
|
November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial
Fern Anari, John O'Neill, Woonyoung Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
Howard I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Neal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Cancer Discovery
|
September 7, 2023
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer
Sandra Santasusagna, Shijia Zhu, Vijayakumar Jawalagatti, et al.
Page
of 26